Dacarbazine
DTIC · Alkylator
Rare hepatic veno-occlusive disease; minimal direct renal injury.
PRE
MildOpen →
Alkylator
Bendamustine
Treanda · Benda
A hybrid alkylator whose biggest renal threat is the tumor it dissolves, not the kidney itself.
ModerateBifunctional alkylator · approved 2008
Chronic lymphocytic leukemiaIndolent / rituximab-refractory B-cell non-Hodgkin lymphomaMantle cell lymphoma (in combinations)
Signature kidney injury
Prerenal / Hemodynamic AKI
Direct nephrotoxicity is uncommon; the principal renal risk is acute kidney injury from tumor lysis syndrome in high-burden disease, classically during the first cycle. TLS with renal failure is documented from the first reported case onward; TMA is rare and case-level.
Source: Hummel et al., Eur J Haematol 2005
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
Glomerulus
Vasculature / EndotheliumGlomerular & peritubular capillaries
Distal Tubule / Collecting Duct
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Mechanism of kidney injury
Rapid cytoreduction in bulky/high-count CLL/lymphoma releases uric acid, potassium and phosphate, causing tumor lysis syndrome with uric acid and calcium-phosphate crystal precipitation, intratubular obstruction and AKI; in CLL even modest tumor burden can produce severe first-cycle TLS. Endothelial injury producing thrombotic microangiopathy has been reported rarely. Leukemic renal infiltration and paraneoplastic glomerular disease (e.g., minimal-change) are alternative CLL-related mechanisms encountered around bendamustine therapy.
Clinical presentation
Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and rising creatinine after the first cycle (TLS); in TMA, microangiopathic hemolytic anemia, thrombocytopenia and AKI. Rarely, nephrotic-range proteinuria from coexisting CLL-associated glomerulopathy.
Onset
TLS within hours to days of the first cycle; TMA delayed and rare.
Reversibility
Reversible
Anticancer mechanism
Bifunctional alkylating agent fusing a nitrogen-mustard group with a purine-analog benzimidazole ring, producing durable DNA cross-links and double-strand breaks with relatively limited cross-resistance to other alkylators. Used for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma (often with rituximab).
Management
Treat established TLS with aggressive IV fluids, rasburicase, electrolyte correction and dialysis if needed; for suspected drug-associated TMA, discontinue and provide supportive care. TLS-related AKI is usually reversible with prompt treatment.
Risk factors
- High tumor burden / high white count (CLL, bulky lymphoma)
- Pre-existing renal impairment
- Volume depletion and high baseline uric acid/LDH
- First treatment cycle
Prevention
- TLS prophylaxis: hydration plus allopurinol or rasburicase per risk
- Identify high-burden patients and monitor labs closely early
- Patient education and close first-cycle monitoring
Note · CLL is not uniformly low risk for TLS - severe first-cycle TLS with multiorgan failure has been reported; intrinsic bendamustine tubular nephrotoxicity is otherwise low.
Clinical depth
Renal dose adjustment
Use with caution and consider dose reduction for CrCl <40 mL/min; not recommended in severe renal impairment per labeling owing to limited data. Active metabolites contribute little to overall effect, but exposure data in advanced CKD are sparse - individualize with pharmacy.
Dialyzability & ESKD dosing
Parent drug is rapidly hydrolyzed/metabolized with short half-life, so it is not meaningfully dialyzable; reported ESKD/HD cases dosed bendamustine successfully with careful timing rather than relying on dialytic removal.
Differential diagnosis
TLS-AKI (hyperuricemia, hyperphosphatemia, hyperkalemia after cytoreduction, crystal/obstructive picture) vs rare drug-associated TMA (microangiopathic hemolysis, thrombocytopenia, normal/low uric acid) vs CLL-intrinsic injury (leukemic infiltration, paraneoplastic minimal-change disease). The TLS biochemistry and its timing to the first cycle are the discriminators.
Monitoring
- Uric acid, potassium, phosphate, calcium and creatinine before and during the first cycle (TLS panel)
- CBC with LDH; schistocytes if TMA suspected
- Renal function across cycles in CLL with renal infiltration
Key trials & series
- Hummel Eur J Haematol 2005 - first reported bendamustine TLS with acute renal failure in CLL
- Garuma Clin Case Rep 2026 - first-cycle bendamustine-rituximab TLS with AKI/multiorgan failure
- Cheson Clin Adv Hematol Oncol 2009 - TLS risk/management framework in CLL including bendamustine
Clinical pearls
- Do not assume CLL is low-risk for TLS - severe, even fatal, first-cycle TLS is reported with bendamustine-rituximab.
- The kidney injury is usually the tumor's doing (TLS), not direct tubular toxicity - prophylaxis and hydration are the main levers.
- Bendamustine has been delivered in ESRD/HD in case reports, so renal failure is not an absolute barrier when no alternative exists.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIThrombotic MicroangiopathyElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of alkylators.
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression; secondary malignancy risk
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Ifosfamide encephalopathy (chloroacetaldehyde)
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- High-dose cyclophosphamide cardiotoxicity
Evidence
8 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkRecurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.Hummel M et al. · Eur J Haematol 2005 · PMID 16313266Early report of bendamustine-associated TLS with acute renal failure in CLL.PMIDLife-Threatening Acute Tumor Lysis Syndrome With Multiorgan Failure Following First Cycle of Bendamustine-Rituximab in Chronic Lymphocytic Leukemia: A Case Report and Brief Review.Garuma MT et al. · Clin Case Rep 2026 · PMID 42004873First-cycle bendamustine-rituximab TLS with AKI and multiorgan failure in CLL.PMIDEtiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.Cheson BD · Clin Adv Hematol Oncol 2009 · PMID 19521331Reviews TLS risk and prophylaxis in CLL, including with bendamustine.PMIDSuccessful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report.Ettleson M et al. · J Oncol Pharm Pract 2018 · PMID 29385883Bendamustine dosing/management in AKI requiring intermittent hemodialysis.PMIDThe use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).Shoji J et al. · BMJ Case Rep 2013 · PMID 23645657Bendamustine administration/management in ESRD on dialysis.PMIDHuge kidneys in a patient with chronic lymphocytic leukaemia.Esposito P et al. · Br J Haematol 2014 · PMID 25384540CLL leukemic renal infiltration with AKI treated with bendamustine.PMID[Minimal-change glomerulonephritis in chronic lymphocytic leukemia: A clinical case].Dzhumabaeva BT et al. · Ter Arkh 2015 · PMID 26978424CLL-associated minimal-change disease/AKI treated with rituximab-bendamustine.PMIDAnticancer drug-induced kidney disorders.Kintzel PE · Drug Saf 2001 · PMID 11219485Class framework for alkylator-related renal dysfunction and microangiopathy.
Related agents
Other agents sharing the same signature kidney injury.